A Phase 1 interventional study of PF-07258669 and Placebo in Healthy Participants, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of PF-07258669 after administration of multiple ascending oral doses to healthy adult participants. Optional cohorts of healthy adult Japanese participants and/or older adult participants may also be evaluated if results in other cohorts support further evaluation. Part B of this study is a 2-period, fixed-sequence, multiple-dose, open-label design to evaluate the effect of PF-07258669 on midazolam PK in healthy adult participants. Part B will be conducted if the results of Part A support further evaluation of PF-07258669.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants of nonchildbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
For optional cohort of older adult participants only: Participants must be in a stable condition at admission. These participants must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination, vital signs assessments, 12-lead (electrocardiogram), and clinical laboratory tests. Participants with mild, chronic, stable disease (eg, controlled hypertension, noninsulin dependent diabetes, osteoarthritis) may be enrolled if deemed medically prudent by the investigator.
(BMI) of 17.5 to 28.5 kg/m2; and a total body weight >50 kg (110 lb).
For optional cohort of older adult participants only: BMI of 17.5 to 32.4 kg/m2; and a total body weight >50 kg (110 lbs). Efforts will be made to enroll at least 3 older adult participants with BMI \<25 kg/m2, if feasible.
Exclusion Criteria:
Evidence or history of hematological, renal, endocrine (including, but not limited to, thyroid disease, diabetes insipidus), pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including, but not limited to, primary polydipsia, obsessive compulsive disorder, anxiety disorder, schizophrenia), neurological (including, but not limited to, seizure disorder, traumatic brain injury), immunodeficiency (including, but not limited to, severe infection that required ICU admission, prolonged hospitalization, or prolonged treatment) or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), as well as presence of clinical laboratory abnormalities.
For optional cohort of older adult participants only: Participants with chronic conditions (eg, hypertension) that are controlled by either diet or stable doses of medications may be included. Recent evidence (ie, within previous 6 months) or history of unstable disease or moderate to severe conditions which would, in the investigator's opinion, interfere with the study evaluations or have an impact on the safety of participants.
Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
For optional cohort of older adult participants only: Participants taking daily prescription or non-prescription medications (that are not moderate or strong cytochrome P450 () inducers or inhibitors) for management of acceptable chronic medical conditions are to be on a stable dose, as defined by no change in dose for the 28 days or 5 half-lives (whichever is longer) before the screening visit.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose level 1: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Carbohydrate High Calorie (HCHC)
Drug: PF-07258669 · Drug: Placebo
Dose level 2: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
Drug: PF-07258669 · Drug: Placebo
Dose level 3: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
Drug: PF-07258669 · Drug: Placebo
Dose level 4: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: Standard Diet (SD)
Drug: PF-07258669 · Drug: Placebo
Dose level 5: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Multiple dose administration of PF-07258669 and placebo over 14 days in Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Drug-drug interaction assessment of pharmacokinetics interaction in PF-07258669 and midazolam Dietary allocation: SD
Drug: PF-07258669 · Drug: Midazolam
Multiple dose administration of PF-07258669 and placebo over 14 days in older adult participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Dose level 6: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Dose level 7: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Dose level 8: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
Drug: PF-07258669 · Drug: Placebo
Dose Level 9: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
Drug: PF-07258669 · Drug: Placebo
Dose Level 10: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
Drug: PF-07258669 · Drug: Placebo
PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Placebo will be administered as tablets; Q8H or Q12H over 14 days
Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study intervention and up to 35 days after last dose of study intervention that were absent before treatment or that worsened after treatment.
Time frame: Part A: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 49 days)
Part A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
Laboratory assessments included clinical chemistry, hematology, and urinalysis. Abnormality was determined based on the criteria specified in the sponsor reporting standards. The primary criteria was less than (\<) 0.8\* lower limit of normal (LLN) for lymphocytes and lymphocytes/leukocytes, greater than (\>) 1.2\* upper limit of normal (ULN) for lymphocytes, eosinophils/leukocytes, monocytes, and monocytes/leukocytes; greater than (\>) 3.0\* ULN for alanine aminotransferase, \>1.3\* ULN for urea nitrogen, cholesterol, and triglycerides; \>1.030 for specific gravity (scalar), greater than or equal to (\>=) 1 for ketones, urine protein, urine hemoglobin, urine bilirubin, leukocyte esterase.
Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Part A: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
Vital signs included: a) supine systolic blood pressure (SBP): change greater than or equal to (\>=) 30 millimeters of mercury (mmHg) increase, postural difference (supine standing) \>= 20 mmHg, standing systolic SBP (mmHg) less than (\<) 90 mmHg, \>= 160 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; b) supine diastolic blood pressure (DBP) \< 50 mmHg, \>= 90 mmHg, change \>= 20 mmHg increase, change \>= 20mmHg decrease; postural difference (supine standing) \>= 10 mmHg; standing \<50 mmHg, value \>=90 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease, C) standing pulse rate (PR) greater than (\>) 140 bpm. Baseline for supine BP and pulse rate was defined as the average of the triplicate measurements collected at the pre-dose (0 hour) assessment on Day 1. Baseline for standing BP, standing pulse rate, respiratory rate and oral body temperature were defined as the pre-dose (0 hour) assessment on Day 1.
Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Part A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria
ECG criteria: QTc corrected using Fridericia's formula (QTCF) interval aggregate in milliseconds (msec): less than or equal to (\<=) change \<= 60 msec. Baseline was defined as the average of the triplicate ECG measurements over the 3 pre-dose measurement times (-1 hour, -0.5 hour, and pre-dose 0 hour; total of 9 ECG measurements) on Day 1.
Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
Time frame: Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -2
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
Time frame: Part A: On Day -2 (2 days prior to dosing)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
Time frame: Part A: On Day 7
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
Time frame: Part A: Day 14
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 21
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
Time frame: Part A: Day 21
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by clinical research unit (CRU) staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
Time frame: Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -1
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
Time frame: Part A: Day -1 (1 day prior to dosing)
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 7
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
Time frame: Part A: Day 7
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 14
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
Time frame: Part A: Day 14
Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 1
Cmax was defined as the maximum observed plasma concentration.
Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
Cmax is the maximum observed plasma concentration.
Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
Cmax was defined as the maximum observed plasma concentration.
Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Part B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 1
AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
Time frame: Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 1
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
Time frame: Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669 on Days 1 and 14
Cmax was defined as the maximum plasma concentration.
Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax,dn) of PF-07258669 on Days 1 and 14
Cmax was defined maximum observed serum concentration. Cmax (dn) was calculated as Cmax/dose.
Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (Tau) (AUCtau) of PF-07258669 on Days 1 and 14
Area under the plasma concentration-time profile from time zero to time tau, the dosing interval, where tau = 8 hours.
Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14
Part A: Dose Normalized Area Under the Curve From Time 0 to Dosing Interval (Tau) (AUCtau, dn) of PF-07258669 on Days 1 and 14
Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14
Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669 on Days 1 and 14
Tmax was defined as the time taken (in hours) to reach the maximum plasma drug concentration.
Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)
Aetau was defined as the amount of unchanged drug recovered in urine during the dosing interval.
Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Part A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)
Aetau% was defined as the percentage of dose recovered in urine as unchanged drug.
Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Part A: Renal Clearance (CLr) of PF-07258669
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Part B: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment.
Time frame: Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)
Part B: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
Vital signs examination included: supine systolic blood pressure with criteria change \>= 30 mmHg decrease, supine diastolic blood pressure with criteria value \>= 90 mmHg and change \>= 20 mmHg decrease.
Time frame: Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)
Part B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria
Following ECG parameters were analyzed: QTCF interval with criteria 450 less than (\<) value less than or equal to (\<=) 480. A standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QTc intervals and QRS complex. On Day 1 at -1 hour (h), -0.5h, and 0h prior to the morning dose, triplicate 12-lead ECGs were obtained approximately 2 to 4 minutes apart at each time point. The average of the triplicate ECG measurements over the 3 pre dose measurement times (total of 9 ECG measurements) collected before morning dose administration on Day 1 served as each participant's baseline QTc value.
Time frame: Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)
Part B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
Laboratory parameters assessed included: hematology (monocytes, monocytes/leukocytes) with primary criteria greater than (\>) 1.2\*upper limit of normal (ULN), clinical chemistry (bilirubin, direct bilirubin and indirect bilirubin with primary criteria \>1.5\*ULN, alanine aminotransferase with primary criteria \>3.0\*ULN, creatine kinase with primary criteria \>2.0\*ULN, urobilinogen with primary criteria greater than or equal to (\>=)1, cholesterol and triglycerides-fasting with primary criteria \>1.3\*ULN), urinalysis (ketones and urine hemoglobin with primary criteria \>=1).
Time frame: Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)
This study consisted of two parts: Part A and Part B. A total of 120 participants were enrolled in the study.
| Milestone | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 8 | 8 | 7 | 10 | 8 | 8 | 8 | 8 | 8 | 12 | 12 | 1 | 5 | 0 |
| Completed | 6 | 8 | 7 | 6 | 9 | 8 | 8 | 8 | 8 | 8 | 12 | 10 | 1 | 5 | 0 |
| Not completed | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study intervention and up to 35 days after last dose of study intervention that were absent before treatment or that worsened after treatment.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 | 8 | 6 | 6 | 9 | 6 | 7 | 4 | 7 | 8 | 8 | 10 | 0 | 3 |
Laboratory assessments included clinical chemistry, hematology, and urinalysis. Abnormality was determined based on the criteria specified in the sponsor reporting standards. The primary criteria was less than (\<) 0.8\* lower limit of normal (LLN) for lymphocytes and lymphocytes/leukocytes, greater than (\>) 1.2\* upper limit of normal (ULN) for lymphocytes, eosinophils/leukocytes, monocytes, and monocytes/leukocytes; greater than (\>) 3.0\* ULN for alanine aminotransferase, \>1.3\* ULN for urea nitrogen, cholesterol, and triglycerides; \>1.030 for specific gravity (scalar), greater than or equal to (\>=) 1 for ketones, urine protein, urine hemoglobin, urine bilirubin, leukocyte esterase.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality | 5 | 6 | 6 | 6 | 9 | 5 | 8 | 7 | 8 | 4 | 11 | 8 | 1 | 3 |
Vital signs included: a) supine systolic blood pressure (SBP): change greater than or equal to (\>=) 30 millimeters of mercury (mmHg) increase, postural difference (supine standing) \>= 20 mmHg, standing systolic SBP (mmHg) less than (\<) 90 mmHg, \>= 160 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; b) supine diastolic blood pressure (DBP) \< 50 mmHg, \>= 90 mmHg, change \>= 20 mmHg increase, change \>= 20mmHg decrease; postural difference (supine standing) \>= 10 mmHg; standing \<50 mmHg, value \>=90 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease, C) standing pulse rate (PR) greater than (\>) 140 bpm. Baseline for supine BP and pulse rate was defined as the average of the triplicate measurements collected at the pre-dose (0 hour) assessment on Day 1. Baseline for standing BP, standing pulse rate, respiratory rate and oral body temperature were defined as the pre-dose (0 hour) assessment on Day 1.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supine SBP Change >= 30mmHg increase | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP postural difference >=20mmHg | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Standing SBP Value < 90 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Standing SBP Value >= 160 mmHg | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 |
| Standing SBP Value >= 30 mmHg increase | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 0 | 1 |
| Standing SBP Value >= 30 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Supine DBP Value >= 30 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Supine DBP value < 50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Supine DBP value >= 90 mmHg | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine DBP change >= 20 mmHg increase | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine DBP change >= 20 mmHg decrease | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP (mmHg) postural difference (supine standing) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
| Standing DBP value < 50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Standing DBP value >= 90 mmHg | 2 | 4 | 1 | 1 | 3 | 1 | 3 | 3 | 1 | 0 | 3 | 2 | 0 | 0 |
| Standing DBP change >= 20 mmHg increase | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0 |
| Standing diastolic BP change >= 20 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 0 |
| Standing PR >140 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECG criteria: QTc corrected using Fridericia's formula (QTCF) interval aggregate in milliseconds (msec): less than or equal to (\<=) change \<= 60 msec. Baseline was defined as the average of the triplicate ECG measurements over the 3 pre-dose measurement times (-1 hour, -0.5 hour, and pre-dose 0 hour; total of 9 ECG measurements) on Day 1.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by clinical research unit (CRU) staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.
| Participants | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cmax was defined as the maximum observed plasma concentration.
| Nanogram per milliliter | Part B Period 1: Midazolam |
|---|---|
| Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 1 | 6.213 ± 43 |
Cmax is the maximum observed plasma concentration.
| Nanogram per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 2) |
|---|---|
| Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 2 | 10.83 ± 27 |
Cmax was defined as the maximum observed plasma concentration.
| Nanogram per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|
| Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 2 | 11.73 ± 30 |
AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
| Nanogram*hour per milliliter | Part B Period 1: Midazolam |
|---|---|
| Part B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 1 | 18.56 ± 47 |
AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
| Nanogram*hour per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 2) |
|---|---|
| Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 2 | 30.27 ± 35 |
AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
| Nanogram*hour per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|
| Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 2 | 40.41 ± 33 |
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
| Nanogram*hour per milliliter | Part B Period 1: Midazolam |
|---|---|
| Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 1 | 19.35 ± 48 |
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
| Nanogram*hour per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 2) |
|---|---|
| Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 2 | 32.84 ± 32 |
AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.
| Nanogram*hour per milliliter | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|
| Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 2 | 41.16 ± 34 |
Cmax was defined as the maximum plasma concentration.
| Nanogram per milliliter | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 19.47 ± 25 | 25.06 ± 22 | 50.41 ± 22 | 45.99 ± 47 | 131.2 ± 32 | 468.3 ± 27 | 987.2 ± 28 | 1263 ± 37 | 1218 ± 42 | 1210 ± 9 |
| Day 14 | 21.96 ± 21 | 27.91 ± 25 | 59.76 ± 29 | 57.08 ± 39 | 165.2 ± 25 | 568.5 ± 26 | 1246 ± 25 | 1464 ± 21 | 1772 ± 19 | 1750 ± 26 |
Cmax was defined maximum observed serum concentration. Cmax (dn) was calculated as Cmax/dose.
| Nanograms per milliliter per milligram | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 9.742 ± 25 | 8.352 ± 22 | 8.403 ± 22 | 7.666 ± 47 | 6.562 ± 32 | 7.803 ± 27 | 7.899 ± 28 | 7.013 ± 37 | 6.770 ± 42 | 6.719 ± 9 |
| Day 14 | 10.99 ± 22 | 9.301 ± 25 | 9.952 ± 29 | 9.515 ± 39 | 8.269 ± 25 | 9.473 ± 26 | 9.982 ± 25 | 8.134 ± 22 | 9.849 ± 19 | 9.723 ± 26 |
Area under the plasma concentration-time profile from time zero to time tau, the dosing interval, where tau = 8 hours.
| Nanograms*hours per (/) milliliter | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 46.27 ± 26 | 60.42 ± 27 | 113.6 ± 15 | 107.2 ± 42 | 388.1 ± 38 | 1207 ± 26 | 2597 ± 29 | 3357 ± 34 | 3361 ± 27 | 3331 ± 13 |
| Day 14 | 62.40 ± 32 | 76.25 ± 30 | 162.0 ± 28 | 147.0 ± 45 | 480.4 ± 28 | 1795 ± 26 | 3946 ± 28 | 5313 ± 31 | 5845 ± 19 | 6074 ± 21 |
| Nanograms*hours/ milliliter/ milligrams | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 23.16 ± 26 | 20.15 ± 27 | 18.93 ± 15 | 17.87 ± 42 | 19.42 ± 38 | 20.14 ± 26 | 20.75 ± 29 | 18.64 ± 34 | 18.67 ± 27 | 18.52 ± 13 |
| Day 14 | 31.21 ± 32 | 25.44 ± 30 | 27.01 ± 28 | 24.47 ± 45 | 24.04 ± 28 | 29.90 ± 26 | 31.57 ± 28 | 29.49 ± 31 | 32.49 ± 19 | 33.74 ± 21 |
Tmax was defined as the time taken (in hours) to reach the maximum plasma drug concentration.
| Hours | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1.000 (0.500 to 1.50) | 1.000 (0.500 to 1.05) | 0.5830 (0.500 to 1.50) | 0.8265 (0.500 to 1.13) | 1.010 (0.500 to 2.00) | 1.000 (0.500 to 1.50) | 1.000 (0.500 to 1.50) | 1.000 (1.00 to 1.05) | 1.000 (0.550 to 1.50) | 0.5830 (0.500 to 1.50) |
| Day 14 | 1.010 (0.500 to 1.52) | 1.000 (0.500 to 1.02) | 0.7415 (0.500 to 1.50) | 0.7665 (0.500 to 1.07) | 1.000 (1.00 to 1.53) | 1.000 (0.500 to 1.05) | 1.000 (0.500 to 1.08) | 1.500 (1.00 to 2.00) | 1.000 (0.500 to 1.50) | 1.000 (1.00 to 1.02) |
Aetau was defined as the amount of unchanged drug recovered in urine during the dosing interval.
| Milligrams | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau) | 0.004304 ± 45 | 0.004490 ± 153 | 0.01690 ± 34 | 0.01462 ± 49 | 0.04039 ± 70 | 0.1440 ± 43 | 0.3173 ± 109 | 0.3371 ± 188 | 0.3146 ± 314 | 0.6581 ± 37 |
Aetau% was defined as the percentage of dose recovered in urine as unchanged drug.
| Percentage of dose | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%) | 0.2152 ± 45 | 0.1496 ± 153 | 0.2814 ± 34 | 0.2436 ± 49 | 0.2020 ± 70 | 0.2400 ± 43 | 0.2536 ± 109 | 0.1872 ± 189 | 0.1748 ± 314 | 0.3654 ± 37 |
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
| Liter/ hour | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Renal Clearance (CLr) of PF-07258669 | 0.06896 ± 37 | 0.05887 ± 171 | 0.1042 ± 44 | 0.09946 ± 33 | 0.08412 ± 48 | 0.08026 ± 55 | 0.08040 ± 116 | 0.06341 ± 241 | 0.05381 ± 350 | 0.1083 ± 31 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment.
| Participants | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|
| Part B: Number of Participants With TEAEs | 2 | 8 | 2 |
Vital signs examination included: supine systolic blood pressure with criteria change \>= 30 mmHg decrease, supine diastolic blood pressure with criteria value \>= 90 mmHg and change \>= 20 mmHg decrease.
| Participants | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|
| Standing systolic blood pressure | 0 | 1 | 1 |
| Standing diastolic blood pressure: value >= 90 mmHg | 0 | 1 | 1 |
| Standing diastolic blood pressure: value change >= 20 mmHg decrease | 0 | 2 | 1 |
Following ECG parameters were analyzed: QTCF interval with criteria 450 less than (\<) value less than or equal to (\<=) 480. A standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QTc intervals and QRS complex. On Day 1 at -1 hour (h), -0.5h, and 0h prior to the morning dose, triplicate 12-lead ECGs were obtained approximately 2 to 4 minutes apart at each time point. The average of the triplicate ECG measurements over the 3 pre dose measurement times (total of 9 ECG measurements) collected before morning dose administration on Day 1 served as each participant's baseline QTc value.
| Participants | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|
| Part B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria | 0 | 0 | 1 |
Laboratory parameters assessed included: hematology (monocytes, monocytes/leukocytes) with primary criteria greater than (\>) 1.2\*upper limit of normal (ULN), clinical chemistry (bilirubin, direct bilirubin and indirect bilirubin with primary criteria \>1.5\*ULN, alanine aminotransferase with primary criteria \>3.0\*ULN, creatine kinase with primary criteria \>2.0\*ULN, urobilinogen with primary criteria greater than or equal to (\>=)1, cholesterol and triglycerides-fasting with primary criteria \>1.3\*ULN), urinalysis (ketones and urine hemoglobin with primary criteria \>=1).
| Participants | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|
| Part B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality | 2 | 4 | 4 |
Collected over Part A: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 49 days), Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: 18-60 Years (HC-HC Diet) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Placebo: 18-60 Years (Standard Diet) | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| PF-07258669 6 mg: 18-60 Years (Standard Diet) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| PF-07258669 20 mg: 18-60 Years (Standard Diet) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| PF-07258669 60 mg: 18-60 Years (Standard Diet) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| PF-07258669 125 mg: 18-60 Years (Standard Diet) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| PF-07258669 180 mg: 18-60 Years (Standard Diet) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Placebo: 18-60 Years (HF-HC Diet) | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Placebo: Japanese 18-60 Years (Standard Diet) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Part B Period 1: Midazolam | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Part B Period 2: PF-07258669 + Midazolam (Day 2) | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Part B Period 2: PF-07258669 + Midazolam (Day 10) | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Event | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurological symptomNervous system disorders | 0/6 | 0/8 | 1/8 | 0/7 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| Event | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Part B Period 1: Midazolam | Part B Period 2: PF-07258669 + Midazolam (Day 2) | Part B Period 2: PF-07258669 + Midazolam (Day 10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/6 | 3/8 | 0/8 | 0/7 | 0/10 | 1/8 | 0/8 | 1/8 | 1/8 | 1/8 | 0/12 | 1/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| HungerGeneral disorders | 0/6 | 0/8 | 0/8 | 0/7 | 1/10 | 0/8 | 1/8 | 4/8 | 0/8 | 0/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 2/11 | 0/9 |
| Dry skinSkin and subcutaneous tissue disorders | 0/6 | 1/8 | 0/8 | 0/7 | 2/10 | 1/8 | 0/8 | 0/8 | 4/8 | 0/8 | 1/12 | 3/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/8 | 0/8 | 0/7 | 1/10 | 3/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| InsomniaPsychiatric disorders | 0/6 | 0/8 | 0/8 | 0/7 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 3/8 | 0/12 | 1/12 | 0/1 | 0/5 | 1/11 | 0/11 | 0/9 |
| NauseaGastrointestinal disorders | 2/6 | 0/8 | 0/8 | 1/7 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 2/6 | 1/8 | 0/8 | 0/7 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| Application site irritationGeneral disorders | 0/6 | 1/8 | 0/8 | 2/7 | 0/10 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| Dry mouthGastrointestinal disorders | 0/6 | 0/8 | 0/8 | 0/7 | 1/10 | 0/8 | 0/8 | 2/8 | 0/8 | 0/8 | 0/12 | 0/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
| DyspepsiaGastrointestinal disorders | 1/6 | 0/8 | 0/8 | 0/7 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 2/8 | 0/12 | 1/12 | 0/1 | 0/5 | 0/11 | 0/11 | 0/9 |
Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention, for the given part of the study (Part A or B).
| Age, Customized(Participants) | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-44 Years | 2 | 7 | 7 | 6 | 7 | 6 | 5 | 5 | 6 | 7 | 10 | 10 | 0 | 5 | 9 | 92 |
| 45-64 Years | 4 | 1 | 1 | 1 | 3 | 2 | 3 | 3 | 2 | 1 | 2 | 2 | 0 | 0 | 2 | 27 |
| Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Sex/Gender, Customized(Participants) | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Male | 6 | 8 | 8 | 7 | 10 | 8 | 8 | 8 | 7 | 8 | 12 | 12 | 0 | 5 | 11 | 118 |
| Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 8 |
| Not Hispanic or Latino | 6 | 7 | 7 | 6 | 10 | 8 | 8 | 7 | 5 | 8 | 11 | 12 | 0 | 5 | 10 | 110 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo: 18-60 Years (HC-HC Diet) | PF-07258669 2 mg: 18-60 Years (HC-HC Diet) | PF-07258669 3 mg: 18-60 Years (HC-HC Diet) | PF-07258669 6 mg: 18-60 Years (HC-HC Diet) | Placebo: 18-60 Years (Standard Diet) | PF-07258669 6 mg: 18-60 Years (Standard Diet) | PF-07258669 20 mg: 18-60 Years (Standard Diet) | PF-07258669 60 mg: 18-60 Years (Standard Diet) | PF-07258669 125 mg: 18-60 Years (Standard Diet) | PF-07258669 180 mg: 18-60 Years (Standard Diet) | Placebo: 18-60 Years (HF-HC Diet) | PF-07258669 180 mg: 18-60 Years (HF-HC Diet) | Placebo: Japanese 18-60 Years (Standard Diet) | PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet) | Midazolam Then PF-07258669 + Midazolam: Standard Diet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 5 | 0 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 3 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 1 | 12 |
| White | 6 | 6 | 8 | 6 | 7 | 8 | 6 | 8 | 7 | 7 | 7 | 11 | 0 | 0 | 10 | 97 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2021 to primary completion in Jul 2023, 20 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-07258669